The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Basit Öğe Kaydı
dc.contributor.authorRazavi, H.
dc.contributor.authorWaked, I.
dc.contributor.authorSarrazin, C.
dc.contributor.authorMyers, R. P.
dc.contributor.authorIdilman, R.
dc.contributor.authorCalinas, F.
dc.contributor.authorVogel, W.
dc.contributor.authorMendes Correa, M. C.
dc.contributor.authorHezode, C.
dc.contributor.authorLazaro, P.
dc.contributor.authorAkarca, U.
dc.contributor.authorAleman, S.
dc.contributor.authorBalik, I.
dc.contributor.authorBerg, T.
dc.contributor.authorBihl, F.
dc.contributor.authorBilodeau, M.
dc.contributor.authorBlasco, A. J.
dc.contributor.authorBrandao Mello, C. E.
dc.contributor.authorBruggmann, P.
dc.contributor.authorButi, M.
dc.contributor.authorCalleja, J. L.
dc.contributor.authorCheinquer, H.
dc.contributor.authorChristensen, P. B.
dc.contributor.authorClausen, M.
dc.contributor.authorCoelho, H. S. M.
dc.contributor.authorCramp, M. E.
dc.contributor.authorDore, G. J.
dc.contributor.authorDoss, W.
dc.contributor.authorDuberg, A. S.
dc.contributor.authorEl-Sayed, M. H.
dc.contributor.authorErgor, G.
dc.contributor.authorEsmat, G.
dc.contributor.authorFalconer, K.
dc.contributor.authorFelix, J.
dc.contributor.authorFerraz, M. L. G.
dc.contributor.authorFerreira, P. R.
dc.contributor.authorFrankova, S.
dc.contributor.authorGarcia-Samaniego, J.
dc.contributor.authorGerstoft, J.
dc.contributor.authorGiria, J. A.
dc.contributor.authorGoncales, F. L., Jr.
dc.contributor.authorGower, E.
dc.contributor.authorGschwantler, M.
dc.contributor.authorGuimaraes Pessoa, M.
dc.contributor.authorHindman, S. J.
dc.contributor.authorHofer, H.
dc.contributor.authorHusa, P.
dc.contributor.authorKaberg, M.
dc.contributor.authorKaita, K. D. E.
dc.contributor.authorKautz, A.
dc.contributor.authorKaymakoglu, S.
dc.contributor.authorKrajden, M.
dc.contributor.authorKrarup, H.
dc.contributor.authorLaleman, W.
dc.contributor.authorLavanchy, D.
dc.contributor.authorMarinho, R. T.
dc.contributor.authorMarotta, P.
dc.contributor.authorMauss, S.
dc.contributor.authorMoreno, C.
dc.contributor.authorMurphy, K.
dc.contributor.authorNegro, F.
dc.contributor.authorNemecek, V.
dc.contributor.authorOrmeci, N.
dc.contributor.authorOvrehus, A. L. H.
dc.contributor.authorParkes, J.
dc.contributor.authorPasini, K.
dc.contributor.authorPeltekian, K. M.
dc.contributor.authorRamji, A.
dc.contributor.authorReis, N.
dc.contributor.authorRoberts, S. K.
dc.contributor.authorRosenberg, W. M.
dc.contributor.authorRoudot-Thoraval, F.
dc.contributor.authorRyder, S. D.
dc.contributor.authorSarmento-Castro, R.
dc.contributor.authorSemela, D.
dc.contributor.authorSherman, M.
dc.contributor.authorShiha, G. E.
dc.contributor.authorSievert, W.
dc.contributor.authorSperl, J.
dc.contributor.authorStarkel, P.
dc.contributor.authorStauber, R. E.
dc.contributor.authorThompson, A. J.
dc.contributor.authorUrbanek, P.
dc.contributor.authorVan Damme, P.
dc.contributor.authorvan Thiel, I.
dc.contributor.authorVan Vlierberghe, H.
dc.contributor.authorVandijck, D.
dc.contributor.authorWedemeyer, H.
dc.contributor.authorWeis, N.
dc.contributor.authorWiegand, J.
dc.contributor.authorYosry, A.
dc.contributor.authorZekry, A.
dc.contributor.authorCornberg, M.
dc.contributor.authorMuellhaupt, B.
dc.contributor.authorEstes, C.
dc.date.accessioned2019-10-27T22:15:26Z
dc.date.available2019-10-27T22:15:26Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractThe disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.en_US
dc.description.sponsorshipGilead SciencesGilead Sciencesen_US
dc.description.sponsorshipWe are grateful to Daniela De Angelis, Ross Harris and Helen Harris at Public Health England for providing us with their calculated HCV progression rates prior to publication. Their progression rates by age cohort were instrumental in developing our estimates. We would also like to thank Rosie Thein for spending time with us discussing her elegant model for HCV progression rate. We would not have been able to get here without her help and guidance. Sylvie Deuffic-Burban, Henri Leleu and Martin Blachier were instrumental with our analysis of France's data. We are also grateful to Virginie Masserey, Jean-Luc Richard and Christian Schaetti of the Federal Office of Public Health (FOPH), who were incredibly generous with their time and data. A number of experts in Portugal provided us with their time and insights. We would like to thank the following individuals for their contribution - Dr. Alexandre Lourenco, Prof. Helena Cortez-Pinto, Dr. Joao Goulao, Luis Mendao, Prof. Paulo Ferrinho and Pedro Pita Barros. This project was supported by Gilead Sciences.en_US
dc.identifier.doi10.1111/jvh.12248en_US
dc.identifier.endpage59en_US
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.pmid24713005en_US
dc.identifier.startpage34en_US
dc.identifier.urihttps://doi.org/10.1111/jvh.12248
dc.identifier.urihttps://hdl.handle.net/11454/50171
dc.identifier.volume21en_US
dc.identifier.wosWOS:000333893200003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Viral Hepatitisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHCVen_US
dc.subjectdiagnosisen_US
dc.subjecttreatmenten_US
dc.subjecthepatitis Cen_US
dc.subjectprevalenceen_US
dc.subjectepidemiologyen_US
dc.subjectdisease burdenen_US
dc.subjectmortalityen_US
dc.subjectincidenceen_US
dc.titleThe present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu